Atom Therapeutics Co. Ltd., a clinical stage biotechnology company founded in 2012, is developing best-in-class small molecule drugs for treatment of metabolic, inflammatory and cardiovascular diseases.

Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout and hyperuricemia. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs on the market.

Another small molecule, ABP-745 for acute gout, has demonstrated safety and efficacy in completed Phase 1 clinical trials in the US. ABP-745 is in Phase 2 clinical trials for acute gout and preparations are underway for Phase 2 clinical trials in other indications.

Latest News from Atom Therapeutics

Atom Therapeutics Joins Gout Education Society on Gout Awareness Day, May 22, to Help Educate the Public on Risk Factors and Treatment Options for This Growing Disease
Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia
Atom Therapeutics to Present Positive Data from a Phase 1 Trial of Its Novel URAT1 Inhibitor for Chronic Gout (ABP-671) in Participants with Chronic Kidney Disease at ACR Convergence 2024
Atom Bioscience Changes Name to Atom Therapeutics To Better Reflect Focus on Development of Best-in-Class Novel Oral Drugs for Inflammatory and Metabolic Diseases